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Abstract We compared adherence to cART and viro-
logical response between indigenous and immigrant
HIV-infected patients in the Netherlands, and investigated
if a possible difference was related to a difference in
the psychosocial variables: HIV-stigma, quality-of-life,
depression and beliefs about medications. Psychosocial
variables were assessed using validated questionnaires
administered during a face-to-face interview. Adherence
was assessed trough pharmacy-refill monitoring. We
assessed associations between psychosocial variables and
non-adherence and having detectable plasma viral load
using logistic regression analyses. Two-hundred-two
patients participated of whom 112 (55%) were immigrants.
Viral load was detectable in 6% of indigenous patients and
in 15% of the immigrants (P \ 0.01). In multivariate
analyses, higher HIV-stigma and prior virological failure
were associated with non-adherence, and depressive
symptoms, prior virological failure and non-adherence with
detectable viral load. Our findings suggest that HIV-stigma
and depressive symptoms may be targets for interventions
aimed at improving adherence and virological response
among indigenous and immigrant HIV-infected patients.
Keywords Adherence  Depressive symptoms  HIV
stigma  Immigrants  cART  Virological response
Introduction
HIV-infected patients have to take lifelong combination
antiretroviral treatment (cART). To avoid treatment failure
and development of resistant virus strains, high levels of
adherence to cART are necessary [1, 2]. However, many
HIV-infected patients have difficulties in maintaining suf-
ficiently high levels of adherence to cART for long periods
of time [3–5].
Nowadays, immigrant patients or patients from ethnic
minority groups form a substantial part of the HIV-infected
patient population in Western European countries [6]. Per-
centages of immigrants among newly diagnosed HIV-
infected patients have been reported to range from 40 to 45%
in these countries [7–10]. Studies conducted in Western
European countries showed that virological and immuno-
logical failure on cART occurs more often in immigrants
than in indigenous patients, with odds ratios ranging from
4.6 to 8.2 [7–9]. A possible explanation for this difference in
response to cART may be a difference in adherence to cART
[3, 11–15]. Several studies indeed found lower adherence to
cART among immigrant populations [16–18].
The largest groups of immigrant HIV-infected patients in
the Netherlands originate from Sub Sahara Africa, Surinam
and the Dutch Antilles. Dutch immigrant patients were
previously shown to have a worse virological response to
cART compared to Dutch indigenous patients [8, 19]. A
qualitative study showed that Dutch HIV-infected immi-
grants had low levels of quality of life, high levels of
depressive symptoms and experienced or perceived high
levels of HIV stigma [20]. Low levels of quality of life, and
higher levels of HIV-stigma and depressive symptoms are
known risk factors for lower levels of adherence to medi-
cation [21, 22] and specifically to cART [23–32]. In addi-
tion, doubts about the necessity of cART and concerns about
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adverse effects were previously found to predict
non-adherence [33–35] and might be different among
HIV-infected immigrant patients when compared with
indigenous patients [36]. There is a marked difference in
demographic characteristics between Dutch indigenous and
immigrant patients. Immigrant patients predominantly have
a heterosexual HIV transmission route and women form a
substantial part [37]. Heterosexuals in general, and espe-
cially women, have been shown to experience more HIV-
stigma and social isolation than white man who have sex
with man (MSM), as they lack the supportive networks and
the relative HIV/AIDS tolerant attitude, commonly experi-
enced within the gay community [38].
The aim of the present study is to compare adherence to
cART and virological treatment response and various psy-
chosocial risk factors for non-adherence, i.e., quality of life,
depressive symptoms, HIV-stigma and beliefs about medi-
cation, between indigenous and immigrant HIV-infected
patients in the Netherlands. We anticipated that these psy-
chosocial risk factors may be more prevalent among immi-
grants, which may be associated with lower levels of
adherence and consequently with a worse virological treat-
ment response (see Fig. 1). Because heterosexuals in gen-
eral, and especially woman, were previously shown to
experience more HIV-stigma than white MSM, the influence
of HIV transmission route and gender are also accounted for
in the model. The second aim was to investigate to what
extent psychosocial risk factors explain a potential differ-
ence in non-adherence and virological response to cART
between indigenous and immigrant HIV-infected patients.
Methods
Participants
Between January 2008 and June 2009, adult non-pregnant
HIV-1 infected patients were asked to participate in the
present study at the outpatient HIV clinic of the Academic
Medical Centre (AMC) in Amsterdam. Patients were eli-
gible if they started cART after 1997, were on cART for at
least 6 months, and had sufficient fluency in Dutch or
English to participate in a face to face interview. Physi-
cians or HIV counselling nurses invited eligible patients to
participate following a planned regular consultation.
We aimed to recruit the following groups of HIV-infected
patients: indigenous Dutch males and females with an HIV
transmission route other than men who have sex with men
(MSM), immigrant males and females with an HIV trans-
mission route other than MSM who were born in Sub Sahara
Africa, Surinam or the Dutch Antilles, and indigenous Dutch
males with HIV transmission route being MSM. This latter
group is the most prevalent at the HIV outpatient clinic of the
AMC. Therefore, a random selection of this group of patients
attending the outpatient clinic was invited to participate, to
prevent oversampling of patients attending the clinic more
often because of having more health problems and of those
more willing to participate. We aimed to include 90 immi-
grant patients and 90 indigenous patients.
Patients signed an informed consent permitting the
investigators to collect data from the patients’ medical files
and to obtain information about refills of ARV medication
at their pharmacies. We assessed quality of life, depressive
symptoms, HIV-stigma, beliefs about medication and self-
reported adherence using standard questionnaires that we
administered during a face-to-face interview. The ques-
tionnaires were available in Dutch or English. Patients
could choose in which language they wanted to be inter-
viewed. The institutional review board of the AMC
Amsterdam approved our study.
Socio-demographic and Clinical Data
From the medical files of participants, we obtained infor-
mation about sex, age, HIV transmission route, immigrant




















Fig. 1 Proposed model for explaining non-adherence and detectable plasma viral load
1682 AIDS Behav (2012) 16:1681–1689
123
ARV medication, type of ARV regimen (NNRTI based, PI
based, NRTI based), instructed treatment interruptions,
prior virological failure since starting cART, and plasma
viral load results. The first viral load measure following the
interview was retrieved. A detectable plasma viral load was
defined as a load [40 copies HIV-RNA/ml. During the
entire study period, the Abbott m2000rt HIV-1 assay was
used.
Questionnaire
We obtained information about prescribed medication,
prescribed number of pills per day and number of forgotten
pills in the past month using self-report questions. We
calculated adherence for each drug taken by the patient
separately. We defined non-adherence as average adher-
ence of all drugs being less than 100%.
We assessed quality of life using the overall quality of
life subscale of the Medical Outcomes Study HIV Health
Survey, i.e., ‘How has the quality of your life been during
the past 4 weeks?’ [39]. Patients could answer on a 5-point
scale ranging from 1 = ‘Very well’ to 5 = ‘Very bad’.
Normally the scale scores are transformed to a range of 0
(worst quality of life) to 100 (best quality of life). How-
ever, in our study other psychosocial factors had scores
with lowest scores meaning the best score and therefore in
our study we used the scores of 1–5 without transforming
them. Consequently, higher scores indicate a poorer quality
of life.
We used the ‘beliefs about medication questionnaire’ to
measure perceived necessity of cART (6 items) and per-
ceived concerns about the potential adverse effects of
cART (5 items) [34]. It employs a 5-point scale ranging
from 1 = ‘strongly’ agree to 5 = ‘strongly disagree’.
Necessity items and concern items were summed and
divided by the number of items producing one score for
perceived necessity (range: 1–5) of cART and one score for
concerns about adverse effects of cART (range: 1–6).
Higher scores indicate low necessity or high concerns
respectively.
Depressive symptoms were assessed by the Centers for
Epidemiologic Studies Depression scale (CES-D) consist-
ing of 20 items such as ‘I felt that everything I did was an
effort’ or ‘People were unfriendly’. Participants could
answer on a 4-point Likert scale ranging from 0 = ‘rarely
or none of the time’ to 3 = ‘Most or all of the time’. Item
scores were summed to get a total score ranging from 0 to
60. We dichotomized the scores at the standard cut-off
score of 15 with scores [15 being indicative of clinically
significant depressive symptoms.
We measured personalized stigma and disclosure con-
cerns with the Berger HIV stigma scale [40, 41]. Examples
of items are ‘People don’t want me around their children
once they know I have HIV’ for the personalized stigma
scale and ‘Most people with HIV are rejected when others
find out’ for the disclosure concerns scale. A four-point
Likert-scale was used, ranging from 1 = ‘strongly dis-
agree’ to 4 = ‘strongly agree’. For each subscale, item
scores were summed to obtain a personalized stigma score
ranging from 18 to 72 and a disclosure concerns score
ranging from 10 to 40 with higher scores indicating more
perceived HIV-stigma.
Pharmacy Refill Adherence
In the Netherlands, each pharmacy has its own registration
system and medication is typically dispensed every
90 days, although this period might vary from 1–3 months.
For each medication refill, pharmacies record date of refill,
collected number of medication, dosing instructions, pre-
scription duration and prescriber. We sent a fax to each
patient’s pharmacies to acquire the data of refilling each
ARV medication for the entire period since the particular
patient had started the current cART-regimen. Details
about the collection of these data are described elsewhere
[42].
We calculated refill adherence in the month prior to the
interview. We chose this period because the self-report
questions about adherence also ask about the previous
month. We took into account leftover medication of former
refills and instructed treatment interruptions as described
previously [42].
For each period between refills we calculated adherence
for each drug with the formula: leftover medication of
former refills ? collected medication at refill/prescribed
medication per day/number of days between refills [43].
We calculated the average adherence of all drugs used
(usually three). Adherence percentages could be higher
than 100%, because of leftover medication and refilling
before the final date of the prescribed treatment time.
Therefore, we truncated the adherence percentages of each
drug separately at 100% before averaging. We defined non-
adherence as an average adherence \100%. We used the
cut-off of \100% adherence to define non-adherence
because we previously showed that this cut-off predicted
plasma HIV RNA significantly and with a narrower con-
fidence interval than other cut-offs [42].
Statistical Analyses
We calculated mean adherence based on self-report and on
pharmacy refill data. Additionally, we calculated percent-
ages of patients being non-adherent and having a detectable
viral load. We calculated Cronbach’s alpha coefficients for
multi-item scales to assess their internal reliability. To
investigate differences between indigenous and immigrant
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HIV-infected patients we conducted Student’s t-tests
for continuous variables and Chi2-tests for categorical
variables.
We conducted stepwise multivariate logistic regression
analyses to investigate variables independently associated
with non-adherence to cART and with having a detectable
viral load, resulting in odds ratios (ORs) for non-adherence
(\100% adherence) and ORs for a detectable viral load.
Variables were kept in the model when significant at
P \ 0.05.
With the four step model suggested by Baron and Kenny
[44], we investigated whether a possible relationship
between immigrant origin and outcome (non-adherence
and detectable viral load) was mediated by psychosocial
risk factors. We therefore established if there were signif-
icant relationships between: (1) immigrant origin and out-
come (non-adherence or detectable viral load), (2)
immigrant origin and the potential mediating risk factor,
and (3) between the potential mediating risk factor and
outcome (non-adherence or detectable viral load). In the
fourth step, we established if the significant association
between immigrant origin and outcome (non-adherence or
detectable viral load) was attenuated or disappeared after
controlling for that particular risk factor. We investigated
the statistical significance of the mediation effect using
bootstrapping to calculate the 95% confidence intervals of
this effect, as described elsewhere [45, 46]. If the 95%
confidence interval does not include zero, the mediation
effect is statistically significant at P \ 0.05.
We conducted a sensitivity analysis using a 6 months
time frame for the pharmacy refill adherence to investigate




Two-hundred-one patients were included in our study.
Table 1 displays the patient characteristics. Forty-five
percent (n = 91) were female, HIV transmission route was
MSM in 45 (22%) patients, and the median age was 43
(IQR: 37–49) years. A total of 112 patients (56%) origi-
nated from Sub Sahara Africa, Surinam or the Dutch
Antilles. Eleven percent of the patients (n = 22) had a
detectable viral load in the first measurement following the
interview. The median plasma viral load was 126 (inter-
quartile range: 60–3,201) copies/ml. Cronbach’s alpha
coefficients were 0.80 for the necessity scale, 0.75 for the
concerns scale, 0.90 for depressive symptoms, 0.94 for
personalized stigma and 0.85 for disclosure concerns.




Data are n (%) or mean (SD)
* P \ 0.05, ** P \ 0.01
Total Indigenous Immigrants t value or
Chi-square
Total 201 89 112
Female 91 (45) 16 (18) 75 (67) 44.5**
Age 43.4 (10.9) 49.2 (10.9) 38.7 (8.4) 8.6**
HIV transmission route MSM 45 (22) 45 (50) 0 (0) 69.1**
Number of years on CART* 5.3 (3.2) 5.5 (3.5) 5.1 (2.9 1.0
Number of years since first positive HIV test 7.1 (4.5) 8.1 (5.2) 6.2 (3.6) 3.1*
Prior virological failure 20 (10) 1 (1) 19(17) 12.1**
cART regimen PI-based 81 (40) 27 (30) 54 (48) 6.2**
\100% adherent self-report 37 (18) 10 (11) 27 (24) 5.5*
\100% adherent pharmacy refill 61 (30) 19 (21) 42 (37) 6.1*
Detectable viral load 22 (11) 5 (6) 17 (15) 4.7**
Quality of Life (range: 1 = best-5 = worst) 2.0 (1.0) 1.8 (0.9) 2.2 (1.1) 2.4*
Perceived necessity of cART
(range: 1 = high–5 = low)
1.9 (0.5) 1.9 (0.5) 1.9 (0.5) 0.8
Concerns of adverse effects
(range: 1 = low–6 = high)
2.8 (0.8) 2.5 (0.6) 4.1 (0.8) 6.7**
Depressive symptoms (range: 0 = low–60 = high) 10.7 (9.7) 6.6 (6.7) 14.1 (10.5) 5.8**
Depressive symptom score ([15) 52 (27) 11 (12) 41 (38) 15.5**
Personalized stigma (range: 18 = low–72 = high) 42.4 (9.1) 37.5 (7.9) 46.5 (8.0) 7.9**
Disclosure concerns (range: 10 = low–40 = high) 28.1 (4.4) 26.8 (4.9) 29.1 (3.7) 4.0**
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Differences Between Indigenous and Immigrant
Patients
Table 1 shows differences between indigenous and immi-
grant HIV-infected patients. Immigrants were more often
female (v2 = 44.5, P = 0.01), were younger (t = -8.6,
P = 0.01), had a shorter time since the first positive HIV
test (t = -3.1, P = 0.01), more often had prior therapy
failure (v2 = 12.2, P \ 0.01) and more often used a PI-
based cART regimen (v2 = 6.2, P \ 0.01).
Mean self-reported adherence was 96% (SD = 14.7)
among immigrant patients and 99% (SD = 9.8) among
indigenous patients (t = -1.45, P = 0.15). Of the immi-
grant patients, 24% was non-adherent based on self-report,
while this percentage was 11% for indigenous patients
(v2 = 5.5, P = 0.02). Mean pharmacy adherence was 89%
(SD = 22) among immigrant patients and 95% (SD = 15)
among indigenous patients (t = -2.3, P = 0.02). Of the
immigrant patients, 37% was non-adherent based on
pharmacy data while this percentage was 21% for indige-
nous patients (v2 = 6.1, P = 0.01). Fifteen percent of the
immigrant patients and 6% of indigenous patients had a
detectable viral load (v2 = 4.7, P = 0.03).
Immigrant patients reported significant poorer quality of
life (t = 2.4, P = 0.01), and higher levels of depressive
symptoms (t = 5.8, P \ 0.01), personalized stigma (t = 7.9,
P \ 0.01) and disclosure concerns (t = 4.0, P \ 0.01). Also,
they reported more concerns about adverse effects of cART
(t = 6.7, P \ 0.01). There was no difference in doubts about
the necessity of cART (t = 0.8, P = 0.4).
Factors Associated with Non-adherence
As pharmacy refill non-adherence was more strongly
associated with a detectable viral load (OR = 4.9; 95% CI
1.9–12.5, P \ 0.01) than self-reported non-adherence
(OR = 3.0; 95% CI 1.1–7.7, P = 0.03), we only describe
the results using pharmacy-refill adherence.
Table 2 shows univariate relationships of possible risk
factors for pharmacy refill non-adherence (i.e., adherence
\100%). Immigrant origin (OR = 2.2; 95% CI: 1.2–4.2,
P = 0.01), personalized stigma (OR = 1.03; 95% CI:
1.0–1.1, P = 0.04) and disclosure concerns (OR = 1.1;
95% CI: 1.0–1.2, P = 0.02) were significantly related to
pharmacy-refill non-adherence in univariate analyses.
Using stepwise multivariate analyses, disclosure concerns
(OR = 1.1; 95% CI: 1.01–1.2, P = 0.048) and prior vi-
rological failure (OR = 3.9; 95% CI: 1.3–9.7, P = 0.011)
were independently related to pharmacy-refill non-
adherence.
Because immigrant origin was significantly associated
with non-adherence (see Table 2) and with disclosure
concerns (see Table 1), and disclosure concerns with non-
adherence (see Table 2), we investigated if the association
between immigrant origin and non-adherence was medi-
ated by disclosure concerns. The association between
immigrant origin and non-adherence was attenuated, but
remained statistically significant, after adjustment for dis-
closure concerns (OR = 1.9; 95% CI: 1.0–3.7, P = 0.05).
The mediation effect for disclosure concerns was statisti-
cally significant at P \ 0.05 (beta value mediation effect
estimate 0.21, 95% confidence interval: 0.02–0.50).
Factors Associated with Detectable Plasma Viral Load
Immigrant origin (OR = 3.0; 95% CI: 1.1–8.6, P = 0.04),
prior virological failure (OR = 8.0; 95% CI: 2.8–22.7,
P \ 0.01), receiving a PI-based regimen (OR = 4.7; 95%
CI: 1.7–12.5, P \ 0.01), non-adherence (OR = 4.9; 95%
CI 1.9–12.5, P \ 0.01), worse quality of life (OR = 1.6;
Table 2 Factors associated
with pharmacy refill adherence
\100%
Non-adherence based on pharmacy refill counts Univariate, OR (95% CI) P
Immigrant origin 2.2 (1.2–4.2) 0.01
Female sex 1.8 (1.0–3.4) 0.05
Younger age, each 1 year decrease 1.01 (0.98–1.04) 0.63
HIV transmission route MSM 0.4 (0.2–1.0) 0.04
Number of years on CART 1.0 (0.9–1.1) 0.9
Number of years since first positive HIV test 1.0 (0.9–1.1) 0.9
Prior virological failure 4.0 (1.6–10.5) \0.01
PI-based regimen 1.4 (0.8–2.6) 0.29
Non-adherence based on self-report 4.7 (2.2–9.9) \0.01
Quality of Life, each 1 point increase 0.8 (0.6–1.1) 0.14
Lower Necessities, each 1 point increase 1.5 (0.8–2.7) 0.19
Higher Concerns, each 1 point increase 1.3 (0.9–1.9) 0.23
Depressive symptoms, score [15 0.7 (0.3–1.4) 0.31
Personalized stigma, each 1 point increase 1.04 (1.00–1.08) 0.04
Disclosure concerns, each 1 point increase 1.1 (1.01–1.2) 0.02
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95% CI: 1.1–2.3, P = 0.02) and having clinically signifi-
cant depressive symptoms (OR = 3.2; 95% CI: 1.3–8.0,
P = 0.01) were significantly associated with having a
detectable viral load in univariate analyses.
In the multivariate analysis, non-adherence (OR = 4.9;
95% CI: 1.8–13.8, P \ 0.001), clinically significant
depressive symptoms (OR = 3.3; 95% CI: 1.2–9.3,
P = 0.02) and prior virological failure (OR = 5.6; 95%
CI: 1.7–18.3, P = \0.001) remained significantly associ-
ated with detectable viral load.
Because immigrant origin was significantly associated
with detectable viral load (see Table 3) and depressive
symptoms (see Table 1), and depressive symptoms with
detectable viral load (see Table 3), we investigated if the
association between immigrant origin and detectable viral
load was mediated by depressive symptoms. The signifi-
cant association between immigrant origin and detectable
viral load disappeared after adjustment for depressive
symptoms (OR = 2.4; 95% CI: 0.8–7.2, P = 0.11). The
mediation effect for depressive symptoms was statistically
significant at P \ 0.05 (beta value mediation effect esti-
mate 0.37, 95% confidence interval: 0.04–0.88).
Sensitivity Analysis
The sensitivity analysis in which we used a 6 months time
frame instead of the 1 month time frame did not change the
results. Immigrants still had significantly lower adherence
than indigenous persons and the variables that were
significantly associated with non-adherence and virological
response remained the same.
Discussion
We found that immigrant patients had significantly lower
levels of adherence to cART, an increased chance of having
a detectable viral load, and higher levels of depressive
symptoms and HIV-stigma than indigenous patients. The
immigrant status per se was not independently associated
with lower levels of adherence and virological outcome, but
this association was mediated by other factors. The associ-
ation between immigrant status and non-adherence was
mediated by HIV-stigma. The association between immi-
grant status and detectable viral load was mediated by
depressive symptoms. We believe our findings suggest that
interventions aimed at enhancing adherence and virological
response to cART among immigrant and indigenous patients
should target HIV-stigma and depressive symptoms.
Our finding that immigrant HIV-infected patients had
lower levels of adherence to cART is consistent with other
studies [17, 47–49]. Moreover, a significantly higher per-
centage of immigrant HIV-infected patients had a detect-
able viral load. This is also consistent with findings from
other studies [7, 17, 18]. Our findings corroborate the
findings of a former qualitative study showing lower levels
of quality of life and higher levels of depressive symptoms
and HIV-stigma among HIV-infected immigrant patients
than among indigenous patients in the Netherlands [19].
Pharmacy refill adherence was a stronger predictor of
virological response than self-reported adherence. We
assessed self-reported adherence during a face-to-face
interview. Consequently, the discrepancy between phar-
macy refill adherence and self-report in predicting viro-
logical response may have been due to social desirability
bias [50]. Moreover, depressive symptoms may have
served as source of reporting bias in self-reported adher-
ence. This issue is the subject of ongoing research.
In contrast with previous studies [28–30, 51, 52], we
found no significant association between depressive symp-
toms and adherence to cART. Remarkably, depressive
symptoms were significantly associated with detectable
viral load. This finding appears to be consistent with those
from previous studies that revealed a relationship between
depressive symptoms and HIV disease progression, inde-
pendent of non-adherence [53–55]. These studies have
suggested that biological factors (e.g., neuroendocrine,
immunological) and behavioural factors, such as smoking
status and health care use, might play a role in this rela-
tionship. Our finding that depressive symptoms are signif-
icantly associated with virological response independent of
pharmacy refill adherence deserves further investigation: is
Table 3 Factors associated with detectable plasma viral load
Detectable viral load Univariate,
OR (95% CI)
P
Immigrant origin 3.0 (1.1–8.5) 0.04
Female sex 2.3 (0.9–5.8) 0.07
Younger age, each 1 year decrease 1.04 (0.99–1.09) 0.10
HIV transmission route MSM 0.3 (0.1–1.4) 0.1
Number of years on CART 1.0 (0.8–.1) 0.7
Number of years since first
positive HIV test
1.0 (0.9–1.1) 0.98
Prior virological failure 8.0 (2.8–22.7) \0.01
PI-based regimen 4.7 (1.7–12.5) \0.01
Non-adherent based on self-report 3.0 (1.1–7.7) 0.03
Non-adherent based on pharmacy refill 4.9 (1.9–12.5) \0.01
Quality of Life, each 1 point increase 1.6 (1.1–2.3) 0.02
Lower Necessities, each 1 point increase 1.2 (0.5–2.7) 0.74
Higher Concerns, each 1 point increase 1.4 (0.8–1.4) 0.30
Depressive symptoms, score [15 3.2 (1.3–8.0) 0.01
Personalized stigma, each 1 point increase 1.03 (1.0–1.08) 0.27
Disclosure concerns, each 1 point
increase
1.1 (1.0–1.2) 0.10
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this attributable to a physiological or behavioural mecha-
nism or does it reflect limitations of our method used to
assess medication adherence?
Our study has several limitations. In our sample, a rela-
tively small percentage of patients had a detectable viral
load, leading to limited statistical power to demonstrate
associations with detectable viral load in a multivariate
model. A second limitation is the fact that the psychosocial
risk factors for non-adherence, i.e., HIV-stigma, depressive
symptoms, beliefs about medication and quality of life
yielded significant inter-correlations of moderate magnitude
(data not shown). This may have hampered our ability to
estimate the effect of individual predictors. This significant
correlation among psychosocial risk factors may be the
result of conceptual overlap and common method variance
as they were all assessed using self-report. A third limitation
is that we used self-report measures in two different lan-
guage versions to assess quality of life, depressive symp-
toms and HIV-stigma among indigenous patients and
immigrants with different countries of origin. The difference
in psychosocial risk factors for non-adherence between
immigrant and indigenous patients may therefore represent a
true difference, but could also reflect in part a difference in
cultural interpretation of the items. However, we believe
these differences are true, because our results are in line with
other studies that have reported higher stigma and depres-
sive symptoms among non-indigenous patients or ethnic
minority populations [19, 56]. Additionally, during the
interviews we got the impression that patients gave similar
meanings to items because they often explained their
answers. Fourth, additional factors may be associated with
non-adherence and a detectable viral load, such as health
care costs. In the Netherlands, health insurance is obligatory
and costs of cART are covered by all health insurance
companies. Nevertheless, quite some of the immigrant
patients mentioned difficulties in paying for transport to the
hospital. Possibly, difficulties in paying for costs indirectly
related to the use of cART may have contributed to the lower
levels of adherence among our immigrant group. The fifth
limitation is the timing of the measurements. Psychosocial
risk factors for non-adherence and non-adherence were
assessed at the same time point, and viral load was measured
at a later point in time. Therefore, we could not predict non-
adherence, but only investigate its associations with risk
factors. A longitudinal study including a larger percentage of
patients with detectable viral loads would allow for inves-
tigating all risk factors for non-adherence and detectable
viral load simultaneously. The last limitation is the validity
of measuring adherence through self-report and pharmacy
refill adherence. Both methods have their limitations and do
not assess actual pill ingestions, although both methods were
significantly related to virological treatment response in the
present study and in previous studies [3, 9, 57–59].
Our study has several strengths. We were able to include
a large percentage of immigrant HIV-infected patients.
These patients are often underrepresented in studies. We
therefore could show that psychosocial factors are indeed
different for immigrant patients in comparison with
indigenous patients. Another strength is that we had nearly
complete data of pharmacy refills, and our study was
strengthened by the combination of different sources of
information including patient-reported data, pharmacy
refill data and laboratory results.
The main implication of our study is the suggestion that
depressive symptoms and HIV-stigma may be targets for
interventions aimed at improving adherence and virologi-
cal response among indigenous and immigrant HIV-
infected patients. Future studies should investigate which
strategies are appropriate to decrease HIV-stigma and
depressive symptoms, and whether reducing HIV-stigma
and depressive symptoms among HIV-infected patients
indeed improves their adherence to cART and their sub-
sequent virological treatment response.
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